(Q34535151)

2 August 2017

0 references

Recent clinical trials with omapatrilat: new developments (English)

1 reference

2 August 2017

Anne Zanchi

1

1 reference

2 August 2017

Marc Maillard

series ordinal

2

1 reference

2 August 2017

Michel Burnier

series ordinal

3

1 reference

2 August 2017

publication date

1 August 2003

1 reference

Current Hypertension Reports

2 August 2017

published in

1 reference

2 August 2017

volume

5

1 reference

2 August 2017

issue

4

1 reference

2 August 2017

page(s)

346-352

1 reference

https://scigraph.springernature.com/pub.10.1007/s11906-003-0045-6

2 August 2017

exact match

0 references

cites work

Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11906-003-0045-6

Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11906-003-0045-6

Angiotensin II type 1 receptor blockers

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11906-003-0045-6

Antihypertensive and antihypertrophic effects of omapatrilat in SHR

21 January 2018

1 reference

12 December 2020

Effects of omapatrilat on systemic arterial function in patients with chronic heart failure

1 reference

12 December 2020

Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial

1 reference

12 December 2020

Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake

1 reference

12 December 2020

Effects of omapatrilat on hemodynamics and safety in patients with heart failure

1 reference

12 December 2020

Vasopeptidase inhibition and angio-oedema

1 reference

12 December 2020

Vasopeptidase inhibitors

1 reference

12 December 2020

Design of the omapatrilat in persons with enhanced risk of atherosclerotic events (OPERA) trial

1 reference

12 December 2020

Effects of stress and behavioral interventions in hypertension: the rise and fall of omapatrilat

1 reference

12 December 2020

Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats

1 reference

12 December 2020

Efficacy and safety of omapatrilat with hydrochlorothiazide for the treatment of hypertension in subjects nonresponsive to hydrochlorothiazide alone

1 reference

12 December 2020

The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure

1 reference

12 December 2020

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

12 December 2020

Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients

1 reference

12 December 2020

Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone.

1 reference

12 December 2020

Vasopeptidase inhibition restores renovascular endothelial dysfunction in salt-induced hypertension

1 reference

12 December 2020

Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).

1 reference

12 December 2020

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

12 December 2020

Omapatrilat--the story of Overture and Octave

1 reference

12 December 2020

Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects.

1 reference

12 December 2020

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

12 December 2020

Comparison of the cardiovascular protection by omapatrilat and lisinopril treatments in DOCA-salt hypertension

1 reference

12 December 2020

Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart Failure

1 reference

12 December 2020

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

12 December 2020

Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure

1 reference

12 December 2020

Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men

1 reference

12 December 2020

Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study

1 reference

12 December 2020

Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril

1 reference

12 December 2020

Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure

1 reference

12 December 2020

Effects of omapatrilat in low, normal, and high renin experimental hypertension

1 reference

12 December 2020

10.1007/S11906-003-0045-6

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

1043885866

0 references

1 reference